TR201907147T4 - Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. - Google Patents

Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. Download PDF

Info

Publication number
TR201907147T4
TR201907147T4 TR2019/07147T TR201907147T TR201907147T4 TR 201907147 T4 TR201907147 T4 TR 201907147T4 TR 2019/07147 T TR2019/07147 T TR 2019/07147T TR 201907147 T TR201907147 T TR 201907147T TR 201907147 T4 TR201907147 T4 TR 201907147T4
Authority
TR
Turkey
Prior art keywords
fgfr inhibitor
tumor drug
intermittent administration
present
salt
Prior art date
Application number
TR2019/07147T
Other languages
English (en)
Inventor
Ochiiwa Hiroaki
Hirai Hiroshi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of TR201907147T4 publication Critical patent/TR201907147T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş aracılığıyla çözülecek problem, FGFR inhibitörünün antitümör etkisi muhafaza edilirken yüksek kan fosfor seviyeleri gibi azaltılmış yan etkilere sahip olan güçlü ve yüksek derecede seçici yeni bir FGFR inhibitörü ve bir antitümör ajan sağlamaktır. Mevcut buluş, Formül (I) ile temsil edilen bir 3,5-disübstitüe benzen alkinil bileşiğini veya kullanılan bir tuzunu içeren bir antitümör ajanı sağlar böylece 3,5-disübstitüe benzen alkinil bileşiği veya bunun bir tuzu, haftada en az iki kere ve en az bir günlük bir dozlama aralığı olmak üzere bir uygulama programıyla uygulanır.
TR2019/07147T 2013-07-18 2014-07-17 Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. TR201907147T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013149963 2013-07-18

Publications (1)

Publication Number Publication Date
TR201907147T4 true TR201907147T4 (tr) 2019-06-21

Family

ID=52346281

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07147T TR201907147T4 (tr) 2013-07-18 2014-07-17 Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.

Country Status (14)

Country Link
US (2) US20160193210A1 (tr)
EP (1) EP3023100B1 (tr)
JP (1) JP6084291B2 (tr)
KR (1) KR101974254B1 (tr)
AU (1) AU2014291161B2 (tr)
DK (1) DK3023100T3 (tr)
ES (1) ES2724929T3 (tr)
HU (1) HUE044273T2 (tr)
PL (1) PL3023100T3 (tr)
PT (1) PT3023100T (tr)
RU (1) RU2664118C2 (tr)
TR (1) TR201907147T4 (tr)
TW (1) TWI574691B (tr)
WO (1) WO2015008839A1 (tr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3023100T3 (pl) 2013-07-18 2019-07-31 Taiho Pharmaceutical Co., Ltd. Lek przeciwnowotworowy do okresowego podawania inhibitora FGFR
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
MX2017012568A (es) * 2015-03-31 2018-01-25 Taiho Pharmaceutical Co Ltd Cristal del compuesto alquinil benceno 3,5-disustituido.
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
WO2020095452A1 (ja) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
JP7161546B2 (ja) 2018-11-09 2022-10-26 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の類縁物質、該化合物の分析方法及び標準品
WO2020110974A1 (ja) * 2018-11-26 2020-06-04 大鵬薬品工業株式会社 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
WO2020170355A1 (ja) * 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Ｆｇｆｒ１変異腫瘍の治療方法
WO2021048613A2 (en) * 2019-09-11 2021-03-18 Tennor Therapeutics Limited Penam derivatives for treating bacterial infections
US20230165862A1 (en) * 2020-04-10 2023-06-01 Taiho Pharmaceutical Co., Ltd. Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
US20230374015A1 (en) * 2020-06-05 2023-11-23 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
BR112022024729A2 (pt) 2020-06-05 2023-02-28 Kinnate Biopharma Inc Inibidores de quinases do receptor do fator de crescimento de fibroblastos
TWI797711B (zh) * 2020-08-13 2023-04-01 大陸商上海和譽生物醫藥科技有限公司 一種fgfr及其突變抑制劑，其製備方法和應用
CN114805359B (zh) * 2021-01-28 2023-10-27 药雅科技(上海)有限公司 炔代杂环化合物fgfr抑制剂的制备方法和用途
CN115028634B (zh) * 2021-03-08 2023-11-28 药雅科技(上海)有限公司 一种炔代吡嗪并杂环类fgfr抑制剂及其制备方法和用途
CN115785103A (zh) * 2022-12-28 2023-03-14 北京康立生医药技术开发有限公司 一种治疗胆管癌药物福巴替尼的合成方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007083A2 (en) 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
JP2007509939A (ja) 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
KR20080063806A (ko) * 2005-10-06 2008-07-07 쉐링 코포레이션 단백질 키나제 억제제로서의 피라졸로피리미딘
SI2090575T1 (sl) * 2005-11-15 2011-08-31 Array Biopharma Inc Postopki in intermediati za pripravo N4-fenil-kinazolin-4-aminskih derivatov
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
JP2009528991A (ja) 2006-02-14 2009-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロ（３，２−ｃ）ピリジン
CN101460161A (zh) 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 α-突触核蛋白毒性的抑制
EP1939197A1 (en) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
JP5347202B2 (ja) 2007-03-28 2013-11-20 ファーマサイクリックス，インク． ブルトンチロシンキナーゼインヒビター
BRPI0914233A2 (pt) 2008-06-19 2015-11-03 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença
GB0819105D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
WO2010125402A1 (en) * 2009-04-30 2010-11-04 Novartis Ag Imidazole derivatives and their use as modulators of cyclin dependent kinases
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011115937A1 (en) 2010-03-14 2011-09-22 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
DE102011015188A1 (de) 2010-03-29 2011-09-29 Herbert Kannegiesser Gmbh Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen
AU2011261185A1 (en) * 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
TWI525097B (zh) 2011-04-06 2016-03-11 Taiho Pharmaceutical Co Ltd Novel imidazole and A compound or a salt thereof
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
SG2014009286A (en) * 2012-01-19 2014-04-28 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
CN104136439B (zh) 2012-02-23 2017-01-18 拜耳知识产权有限责任公司 取代的苯并噻吩基‑吡咯并三嗪及其用途
RU2618423C2 (ru) 2012-07-02 2017-05-03 Тайхо Фармасьютикал Ко., Лтд. Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение
EP2692740A1 (en) 2012-07-30 2014-02-05 Le Centre National De La Recherche Scientifique Glycan compositions, processes for preparing the same and their uses as a drug
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
BR112015021423A2 (pt) 2013-03-06 2017-07-18 Genentech Inc métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
DK3543355T3 (da) 2013-06-20 2021-03-01 Taiho Pharmaceutical Co Ltd Fremgangsmåde til forudsigelse af terapeutisk effektivitet for pi3k/akt/mtor-hæmmer på basis af phlda1- eller pik3c2b-ekspression
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
PL3023100T3 (pl) 2013-07-18 2019-07-31 Taiho Pharmaceutical Co., Ltd. Lek przeciwnowotworowy do okresowego podawania inhibitora FGFR
US10350214B2 (en) 2014-04-25 2019-07-16 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105859721B (zh) 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法
CN111943962A (zh) 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
MX2017012568A (es) 2015-03-31 2018-01-25 Taiho Pharmaceutical Co Ltd Cristal del compuesto alquinil benceno 3,5-disustituido.
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EA201890161A1 (ru) 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物

Also Published As

Publication number Publication date
PL3023100T3 (pl) 2019-07-31
EP3023100B1 (en) 2019-03-13
US10894048B2 (en) 2021-01-19
US20160193210A1 (en) 2016-07-07
RU2016105133A (ru) 2017-08-23
AU2014291161B2 (en) 2018-04-26
TWI574691B (zh) 2017-03-21
PT3023100T (pt) 2019-05-29
WO2015008839A1 (ja) 2015-01-22
US20190183897A1 (en) 2019-06-20
HUE044273T2 (hu) 2019-10-28
JPWO2015008839A1 (ja) 2017-03-02
EP3023100A1 (en) 2016-05-25
DK3023100T3 (da) 2019-05-27
KR20160032186A (ko) 2016-03-23
AU2014291161A1 (en) 2016-02-25
JP6084291B2 (ja) 2017-02-22
TW201536294A (zh) 2015-10-01
RU2016105133A3 (tr) 2018-02-28
EP3023100A4 (en) 2017-01-04
KR101974254B1 (ko) 2019-04-30
ES2724929T3 (es) 2019-09-17
RU2664118C2 (ru) 2018-08-15

Similar Documents

Publication Publication Date Title
TR201907147T4 (tr) Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2015017532A (es) Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
TR201904614T4 (tr) Novel pyrazole derivative.
EA201690322A1 (ru) Терапевтически активные соединения и способы их применения
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
TR201904327T4 (tr) Dimetilbenzoik asit bileşikleri.
TR201909447T4 (tr) Aramkol tuzları.
TR201819576T4 (tr) Düşük Dozda İrinotekan Hidroklorid Hidrat İçeren Antitümör Ajanı
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
EA201590250A1 (ru) Производные карбамат/мочевины
EA201692270A1 (ru) Производные нафтиридиндиона
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
EA201591649A1 (ru) Составы с органическими соединениями
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
CY1121708T1 (el) Ενωσεις ουριας ινδανυλιου που αναστελλουν την ρ38 map kιναση
PL405129A1 (pl) Nowe peptydomimetyki o aktywności antyangiogennej
EA033106B1 (ru) Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения
EA201690236A1 (ru) Производные индол-3-карбинола
CY1120984T1 (el) Φαρμακευτικος συνδυασμος που περιεχει εναν αναστολεα κινασης φωσφατιδυλινοσιτολης-3 και εναν αναστολεα αρωματασης